Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Other solid neoplasm 2Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Letrozole 34Fulvestrant 31Specimen Handling 29ribociclib 22pembrolizumab 22Paclitaxel 21Magnetic Resonance Spectroscopy 20palbociclib 19Trastuzumab 19Anastrozole 19Carboplatin 18Capecitabine 18exemestane 17abemaciclib 16Biopsy 16Tamoxifen 15pertuzumab 14trastuzumab deruxtecan 12Cyclophosphamide 10Taxes 9Radiotherapy 8Goserelin 8Docetaxel 8giredestrant 7Standard of Care 7130-nm albumin-bound paclitaxel 7inavolisib 6eribulin 6elacestrant 6atezolizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sintilimab × Breast × 30 days × Clear all
NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
58 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡